Activity content starts in:
Industry Webcast
VEOZAH™ (fezolinetant) For the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause Industry Webcast Sponsored by Astellas Pharma US, Inc.; Not for CME/CE Credit
In this session, we will review an FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause, including indication, mechanism of action, and clinical safety and efficacy.
IMPORTANT SAFETY INFORMATION
Contraindications
VEOZAH is contraindicated in women with any of the following:
- Known cirrhosis
- Severe renal impairment or end-stage renal disease
- Concomitant use with CYP1A2 inhibitors
Please see additional Important Safety Information throughout the presentation.
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 9/25/2024
Expiration Date: 9/25/2024
Topics
Faculty
Faculty
Supporters and Partners
Industry Sponsor
Astellas Pharma US, Inc.
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.